SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like How Gilead Lost $7.8B in October Alone November 2, 2017 Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017 FDA Approves 23andMe’s Direct-to-Consumer Genetic Test for Cancer March 6, 2018
Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017